OBJECTIVE
The aim of the study is to evaluate overall survival (OS) and radiation pneumonitis (RP) in patients aged ≥70 years with stage III non-small cell lung cancer (NSCLC) treated with definitive radiotherapy (RT) or concurrent chemoradiotherapy (CRT).
METHODS
A retrospective analysis included 104 patients. Clinical, dosimetric, and treatment-related factors were assessed. Survival was analyzed using Kaplan–Meier and Cox regression models.
RESULTS
Median OS was 21 months (95% confidence interval: 17–24). Univariate analysis showed associations between OS and Karnofsky Performance Status, tumor volume, total mean lung dose (tMLD), histopa-thology, chemotherapy use and regimen, RP grade, and RT response. Multivariate analysis identified planning target volume, tMLD, RT response, and RP as independent predictors of OS. RP severity was significantly associated with comorbidities, lymph node location, chemotherapy regimen, and higher lung dose-volume parameters (tV50–60, iV45–60).
CONCLUSION
OS in elderly stage III NSCLC patients is influenced by tumor response and lung dosimetry. RP inde-pendently worsens survival. Treatment decisions should rely on functional status rather than age, and concurrent CRT is feasible in selected patients.
Keywords: Concurrent chemoradiotherapy; definitive radiotherapy; geriatric patients; non-small cell lung cancer; overall survival.